AbbVie Inc. (ABBV)
$274.36-2.40%Close
BUYBULL · day 22
Key stats
Short interest · FINRA settlement 2026-09-30
52-week IV7.4%–49.1%
- Market cap
- $484.7B
- Beta
- 0.28
- Div yield
- 3.02%
- P/E (TTM)
- 79.88
- IV-%ile
- 2
- IV ATM
- 15.3%
- Short % float
- 0.92%
- Days to cover
- 4.1
- SI change
- -16.5%
- 1W
- +2.88%
- 1M
- +4.84%
- vs SPY 1W
- +3.01%
- vs SPY 1M
- +2.33%
Industry peers
FMP comparable companies · ranked by market cap
- LLYBUYEli Lilly and Company$1.1TRECOVERYQ 21$1179.27-1.36%
- JNJSELLJohnson & Johnson$630.0BBEARQ 22$261.44-5.73%
- MRKSELLMerck & Co., Inc.$359.6BBEARQ 11$145.60-2.39%
- RHHBYRoche Holding AG$344.8B$54.09
- NVSBUYNovartis AG$273.2BRECOVERYQ 20$143.75-0.99%
- AZNSELLAstraZeneca PLC$246.9BRECOVERYQ 20$159.20-1.59%
- AMGNBUYAmgen Inc.$223.9BRECOVERYQ 22$414.87-1.13%
- PFESELLPfizer Inc.$161.2BBULLQ 13$28.28-0.11%
- BMYSELLBristol-Myers Squibb Company$120.8BBEARQ 10$59.12-1.58%
- GSKSELLGSK plc$93.2BRECOVERYQ 14$46.50-1.39%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on ABBV?
- LOPJLB’s latest quantitative signal on AbbVie Inc. (ABBV) is BUY in a BULL regime. Signals are updated daily.
- What market regime is ABBV in?
- AbbVie Inc. (ABBV) is currently classified in the BULL HMM market regime on LOPJLB.
- What does AbbVie Inc. (ABBV) do?
- AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe p…